Eton Pharmaceuticals stock gains 6.98 percent after Q2 results
Published on 09/25/2026 at 09:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eton Pharmaceuticals stock gained 6.98 percent to USD 59.49 on Nasdaq on September 24, 2026, giving the rare disease specialist a market capitalization of USD 1.63 billion. The move followed a second quarter report that combined record revenue with higher guidance.
Revenue beats consensus by USD 10.48 million
StockTitan identifies August 13, 2026 as the reporting date for Eton Pharmaceuticals' second quarter 2026 results and says the company reported record quarterly revenue, raised guidance and delivered stronger profitability.
MarketBeat puts second quarter revenue at USD 37.59 million against a consensus estimate of USD 27.11 million. The USD 10.48 million gap equals 38.66 percent above the estimate, making revenue execution the clearest quantified driver in the latest report.
Rare disease portfolio expands
Eton had eleven commercial rare disease products in September 2026, including Increlex, Alkindi Sprinkle, Khindivi and Impavido, according to the company announcement carried by GlobeNewswire. The same announcement listed five late-stage candidates, including ASN-001, AMGLIDIA, ET-700, ET-800 and a ZENEO hydrocortisone autoinjector.
The portfolio count matters because Eton's revenue base is tied to marketed treatments rather than a single development asset. The September 2026 launch of Impavido added another commercial product to that base, while the late-stage candidates preserve a pipeline component alongside current sales.
Stock remains below yearly high
At USD 59.49 on September 24, 2026, Eton Pharmaceuticals stock stood USD 6.88 below its 52-week high of USD 66.37 and 10.37 percent below that level. Its 52-week low was USD 14.27, placing the latest quote USD 45.22 above the low.
The combination of a 6.98 percent daily advance, USD 1.63 billion market capitalization and revenue of USD 37.59 million gives the stock a clear market and operating reference. For investors, the next central test is whether the expanded product base can sustain the revenue gap over consensus in subsequent reporting periods.
Eton Pharmaceuticals stock snapshot
- Company: Eton Pharmaceuticals, Inc.
- Ticker: ETON
- Trading venue: Nasdaq
- Price as of September 24, 2026: USD 59.49
- Market capitalization: USD 1,629,571,377 (as of September 24, 2026)
- 52-week range: USD 14.27-66.37 (as of September 24, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
